REFERENCES
2. Myers J, Prakash M, Froelicher V, Do D, Partington S, Atwood JE. Exercise capacity and mortality among men referred for exercise testing. N Engl J Med 2002;346:793-801.
3. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2013;128:e240-327.
4. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. J Am Coll Cardiol 2022;79:1757-80.
5. Kittleson MM, Panjrath GS, Amancherla K, et al. 2023 ACC expert consensus decision pathway on management of heart failure with preserved ejection fraction: a report of the American college of cardiology solution set oversight committee. J Am Coll Cardiol 2023;81:1835-78.
6. Pieske B, Tschöpe C, de Boer RA, et al. How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur Heart J 2019;40:3297-317.
7. Paulus WJ, Tschöpe C, Sanderson JE, et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the heart failure and echocardiography associations of the European society of cardiology. Eur Heart J 2007;28:2539-50.
8. Iwanaga Y, Nishi I, Furuichi S, et al. B-type natriuretic peptide strongly reflects diastolic wall stress in patients with chronic heart failure: comparison between systolic and diastolic heart failure. J Am Coll Cardiol 2006;47:742-8.
9. Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002;347:161-7.
10. Horwich TB, Hamilton MA, Fonarow GC. B-type natriuretic peptide levels in obese patients with advanced heart failure. J Am Coll Cardiol 2006;47:85-90.
11. Reddy YNV, Carter RE, Obokata M, Redfield MM, Borlaug BA. A simple, evidence-based approach to help guide diagnosis of heart failure with preserved ejection fraction. Circulation 2018;138:861-70.
12. Bluemke DA, Kronmal RA, Lima JA, et al. The relationship of left ventricular mass and geometry to incident cardiovascular events: the MESA (multi-ethnic study of atherosclerosis) study. J Am Coll Cardiol 2008;52:2148-55.
13. Cheng S, Fernandes VR, Bluemke DA, McClelland RL, Kronmal RA, Lima JA. Age-related left ventricular remodeling and associated risk for cardiovascular outcomes: the multi-ethnic study of atherosclerosis. Circ Cardiovasc Imaging 2009;2:191-8.
14. Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American society of echocardiography and the European association of cardiovascular imaging. J Am Soc Echocardiogr 2015;28:1-39.e14.
15. Zemrak F, Ambale-Venkatesh B, Captur G, et al. Left atrial structure in relationship to age, sex, ethnicity, and cardiovascular risk factors: MESA (multi-ethnic study of atherosclerosis). Circ Cardiovasc Imaging 2017;10:e005379.
16. La Gerche A, Howden EJ, Haykowsky MJ, Lewis GD, Levine BD, Kovacic JC. Heart failure with preserved ejection fraction as an exercise deficiency syndrome: JACC focus seminar 2/4. J Am Coll Cardiol 2022;80:1177-91.
17. Redfield MM, Borlaug BA. Heart failure with preserved ejection fraction: a review. JAMA 2023;329:827-38.
18. Borlaug BA, Nishimura RA, Sorajja P, Lam CS, Redfield MM. Exercise hemodynamics enhance diagnosis of early heart failure with preserved ejection fraction. Circ Heart Fail 2010;3:588-95.
19. Borlaug BA. Evaluation and management of heart failure with preserved ejection fraction. Nat Rev Cardiol 2020;17:559-73.
20. Wolsk E, Bakkestrøm R, Thomsen JH, et al. The influence of age on hemodynamic parameters during rest and exercise in healthy individuals. JACC Heart Fail 2017;5:337-46.
21. Zierath R, Claggett B, Arthur V, et al. Changes in pulmonary artery pressure late in life: the atherosclerosis risk in communities (ARIC) study. J Am Coll Cardiol 2023;82:2179-92.
22. Selby DE, Palmer BM, LeWinter MM, Meyer M. Tachycardia-induced diastolic dysfunction and resting tone in myocardium from patients with a normal ejection fraction. J Am Coll Cardiol 2011;58:147-54.
23. Runte KE, Bell SP, Selby DE, et al. Relaxation and the role of calcium in isolated contracting myocardium from patients with hypertensive heart disease and heart failure with preserved ejection fraction. Circ Heart Fail 2017;10:e004311.
24. Silverman DN, Rambod M, Lustgarten DL, Lobel R, LeWinter MM, Meyer M. Heart rate-induced myocardial Ca2+ retention and left ventricular volume loss in patients with heart failure with preserved ejection fraction. J Am Heart Assoc 2020;9:e017215.
26. Reddy YNV, Koepp KE, Carter R, et al. Rate-adaptive atrial pacing for heart failure with preserved ejection fraction: the RAPID-HF randomized clinical trial. JAMA 2023;329:801-9.
27. Molnár AÁ, Nádasy GL, Dörnyei G, et al. The aging venous system: from varicosities to vascular cognitive impairment. Geroscience 2021;43:2761-84.
28. Sorimachi H, Burkhoff D, Verbrugge FH, et al. Obesity, venous capacitance, and venous compliance in heart failure with preserved ejection fraction. Eur J Heart Fail 2021;23:1648-58.
29. Lakatta EG, Mitchell JH, Pomerance A, Rowe GG. Human aging: changes in structure and function. J Am Coll Cardiol 1987;10:42A-7A.
30. de la Espriella R, Palau P, Losito M, et al. Left ventricular volume and maximal functional capacity in heart failure with preserved ejection fraction: size matters. Eur J Heart Fail 2024.
31. Hieda M, Sarma S, Hearon CM Jr, et al. One-year committed exercise training reverses abnormal left ventricular myocardial stiffness in patients with stage B heart failure with preserved ejection fraction. Circulation 2021;144:934-46.
32. Driussi C, Ius A, Bizzarini E, et al. Structural and functional left ventricular impairment in subjects with chronic spinal cord injury and no overt cardiovascular disease. J Spinal Cord Med 2014;37:85-92.
33. Wang CC, Chang CT, Lin CL, Huang BR, Kao CH. Spinal cord injury is associated with an increased risk of atrial fibrillation: a population-based cohort study. Heart Rhythm 2016;13:416-23.
34. Yoo JE, Kim M, Kim B, et al. Increased risk of myocardial infarction, heart failure, and atrial fibrillation after spinal cord injury. J Am Coll Cardiol 2024;83:741-51.
35. Perhonen MA, Franco F, Lane LD, et al. Cardiac atrophy after bed rest and spaceflight. J Appl Physiol 2001;91:645-53.
36. Chow GV, Marine JE, Fleg JL. Epidemiology of arrhythmias and conduction disorders in older adults. Clin Geriatr Med 2012;28:539-53.
37. Mesquita T, Zhang R, Cho JH, et al. Mechanisms of sinoatrial node dysfunction in heart failure with preserved ejection fraction. Circulation 2022;145:45-60.
38. Andersen ØS, Krogh MR, Boe E, et al. Left bundle branch block increases left ventricular diastolic pressure during tachycardia due to incomplete relaxation. J Appl Physiol 2020;128:729-38.
39. Meyer M, LeWinter MM. Heart rate and heart failure with preserved ejection fraction: time to slow β-blocker use? Circ Heart Fail 2019;12:e006213.
41. Ostchega Y, Porter KS, Hughes J, Dillon CF, Nwankwo T. Resting pulse rate reference data for children, adolescents, and adults: United States, 1999-2008. Natl Health Stat Rep 2011;41:1-16.
42. Gillum RF. Epidemiology of resting pulse rate of persons ages 25-74-data from NHANES 1971-74. Public Health Rep 1992;107:193-201.
44. Borlaug BA, Melenovsky V, Russell SD, et al. Impaired chronotropic and vasodilator reserves limit exercise capacity in patients with heart failure and a preserved ejection fraction. Circulation 2006;114:2138-47.
45. Hall JE, do Carmo JM, da Silva AA, Wang Z, Hall ME. Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms. Circ Res 2015;116:991-1006.
46. Russo C, Jin Z, Homma S, et al. Effect of obesity and overweight on left ventricular diastolic function: a community-based study in an elderly cohort. J Am Coll Cardiol 2011;57:1368-74.
47. Wright JT Jr, Williamson JD, Whelton PK, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 2015;373:2103-16.
48. Soliman EZ, Rahman AF, Zhang ZM, et al. Effect of intensive blood pressure lowering on the risk of atrial fibrillation. Hypertension 2020;75:1491-6.
49. Solomon SD, McMurray JJV, Anand IS, et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med 2019;381:1609-20.
50. Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 2021;385:1451-61.
51. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med 2022;387:205-16.
52. Solomon SD, McMurray JJV, Claggett B, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med 2022;387:1089-98.
53. Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-hormone-receptor agonist retatrutide for obesity - a phase 2 trial. N Engl J Med 2023;389:514-26.
54. Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med 2023;389:1069-84.
56. Meyer M, Du Fay Lavallaz J, Benson L, Savarese G, Dahlström U, Lund LH. Association between β-blockers and outcomes in heart failure with preserved ejection fraction: current insights from the SwedeHF registry. J Card Fail 2021;27:1165-74.
57. Goyal P, Kim M, Krishnan U, et al. Post-operative atrial fibrillation and risk of heart failure hospitalization. Eur Heart J 2022;43:2971-80.
58. Solomon SD, Vaduganathan M, Claggett BL, et al. Baseline characteristics of patients with HF with mildly reduced and preserved ejection fraction: DELIVER trial. JACC Heart Fail 2022;10:184-97.
59. Shah SJ, Kitzman DW, Borlaug BA, et al. Phenotype-specific treatment of heart failure with preserved ejection fraction: a multiorgan roadmap. Circulation 2016;134:73-90.
60. Kittleson MM, Ruberg FL, Ambardekar AV, et al. 2023 ACC expert consensus decision pathway on comprehensive multidisciplinary care for the patient with cardiac amyloidosis: a report of the american college of cardiology solution set oversight committee. J Am Coll Cardiol 2023;81:1076-126.
61. Sipe JD, Benson MD, Buxbaum JN, et al. Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification International Society of Amyloidosis 2016 Nomenclature Guidelines. Amyloid 2016;23:209-13.
62. González-López E, Gallego-Delgado M, Guzzo-Merello G, et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J 2015;36:2585-94.
63. Kitzman DW, Haykowsky MJ, Tomczak CR. Making the case for skeletal muscle myopathy and its contribution to exercise intolerance in heart failure with preserved ejection fraction. Circ Heart Fail 2017;10:e004281.
64. Shah SJ, Borlaug BA, Kitzman DW, et al. Research priorities for heart failure with preserved ejection fraction: national heart, lung, and blood institute working group summary. Circulation 2020;141:1001-26.
65. Paulus WJ, Tschöpe C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol 2013;62:263-71.
66. Hahn VS, Knutsdottir H, Luo X, et al. Myocardial gene expression signatures in human heart failure with preserved ejection fraction. Circulation 2021;143:120-34.
67. Ye B, Bradshaw AD, Abrahante JE, et al. Left ventricular gene expression in heart failure with preserved ejection fraction-profibrotic and proinflammatory pathways and genes. Circ Heart Fail 2023;16:e010395.
68. Liu CY, Liu YC, Wu C, et al. Evaluation of age-related interstitial myocardial fibrosis with cardiac magnetic resonance contrast-enhanced T1 mapping: MESA (multi-ethnic study of atherosclerosis). J Am Coll Cardiol 2013;62:1280-7.
69. Mohammed SF, Hussain S, Mirzoyev SA, Edwards WD, Maleszewski JJ, Redfield MM. Coronary microvascular rarefaction and myocardial fibrosis in heart failure with preserved ejection fraction. Circulation 2015;131:550-9.
70. Fraticelli A, Josephson R, Danziger R, Lakatta E, Spurgeon H. Morphological and contractile characteristics of rat cardiac myocytes from maturation to senescence. Am J Physiol 1989;257:H259-65.
71. Janczewski AM, Lakatta EG. Modulation of sarcoplasmic reticulum Ca2+ cycling in systolic and diastolic heart failure associated with aging. Heart Fail Rev 2010;15:431-45.
73. Ferrucci L, Fabbri E. Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty. Nat Rev Cardiol 2018;15:505-22.
74. Zile MR, Baicu CF, Ikonomidis JS, et al. Myocardial stiffness in patients with heart failure and a preserved ejection fraction: contributions of collagen and titin. Circulation 2015;131:1247-59.
75. Messias LR, Messias AC, de Miranda SM, et al. Abnormal adrenergic activation is the major determinant of reduced functional capacity in heart failure with preserved ejection fraction. Int J Cardiol 2016;203:900-2.
76. van Heerebeek L, Borbély A, Niessen HW, et al. Myocardial structure and function differ in systolic and diastolic heart failure. Circulation 2006;113:1966-73.
77. Borbély A, Falcao-Pires I, van Heerebeek L, et al. Hypophosphorylation of the stiff N2B titin isoform raises cardiomyocyte resting tension in failing human myocardium. Circ Res 2009;104:780-6.
78. Andersen MJ, Hwang SJ, Kane GC, et al. Enhanced pulmonary vasodilator reserve and abnormal right ventricular: pulmonary artery coupling in heart failure with preserved ejection fraction. Circ Heart Fail 2015;8:542-50.
79. Shah AM, Cikes M, Prasad N, et al. Echocardiographic features of patients with heart failure and preserved left ventricular ejection fraction. J Am Coll Cardiol 2019;74:2858-73.
80. Sarma S, Stoller D, Hendrix J, et al. Mechanisms of chronotropic incompetence in heart failure with preserved ejection fraction. Circ Heart Fail 2020;13:e006331.
81. Palau P, Seller J, Domínguez E, et al. Effect of β-blocker withdrawal on functional capacity in heart failure and preserved ejection fraction. J Am Coll Cardiol 2021;78:2042-56.
82. Nanayakkara S, Byrne M, Mak V, Carter K, Dean E, Kaye DM. Extended-release oral milrinone for the treatment of heart failure with preserved ejection fraction. J Am Heart Assoc 2020;9:e015026.
83. Kaye DM, Nanayakkara S, Vizi D, Byrne M, Mariani JA. Effects of milrinone on rest and exercise hemodynamics in heart failure with preserved ejection fraction. J Am Coll Cardiol 2016;67:2554-6.
84. Burkhoff D, Borlaug BA, Shah SJ, et al. Levosimendan improves hemodynamics and exercise tolerance in PH-HFpEF: results of the randomized placebo-controlled HELP trial. JACC Heart Fail 2021;9:360-70.
85. Aiad N, du Fay de Lavallaz J, Zhang MJ, et al. Cilostazol in patients with heart failure and preserved ejection fraction-The CLIP-HFpEF trial. ESC Heart Fail 2024.
86. Redfield MM, Chen HH, Borlaug BA, et al. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA 2013;309:1268-77.
87. Zile MR, Baicu CF, Gaasch WH. Diastolic heart failure-abnormalities in active relaxation and passive stiffness of the left ventricle. N Engl J Med 2004;350:1953-9.
88. Eisner DA, Caldwell JL, Trafford AW, Hutchings DC. The control of diastolic calcium in the heart: basic mechanisms and functional implications. Circ Res 2020;126:395-412.
89. Luo W, Grupp IL, Harrer J, et al. Targeted ablation of the phospholamban gene is associated with markedly enhanced myocardial contractility and loss of beta-agonist stimulation. Circ Res 1994;75:401-9.
90. Meyer M, Bluhm WF, He H, et al. Phospholamban-to-SERCA2 ratio controls the force-frequency relationship. Am J Physiol 1999;276:H779-85.
91. Shah AM, Claggett B, Sweitzer NK, et al. Prognostic importance of impaired systolic function in heart failure with preserved ejection fraction and the impact of spironolactone. Circulation 2015;132:402-14.
92. Mulieri LA, Hasenfuss G, Leavitt B, Allen PD, Alpert NR. Altered myocardial force-frequency relation in human heart failure. Circulation 1992;85:1743-50.
93. Pieske B, Kretschmann B, Meyer M, et al. Alterations in intracellular calcium handling associated with the inverse force-frequency relation in human dilated cardiomyopathy. Circulation 1995;92:1169-78.
94. Tamargo M, Martínez-Legazpi P, Espinosa MÁ, et al. Increased chamber resting tone is a key determinant of left ventricular diastolic dysfunction. Circ Heart Fail 2023;16:e010673.
95. Kagami K, Obokata M, Harada T, et al. Diastolic filling time, chronotropic response, and exercise capacity in heart failure and preserved ejection fraction with sinus rhythm. J Am Heart Assoc 2022;11:e026009.
96. Leite-Moreira AF, Correia-Pinto J, Gillebert TC. Afterload induced changes in myocardial relaxation: a mechanism for diastolic dysfunction. Cardiovasc Res 1999;43:344-53.
97. Prinzen FW, Auricchio A, Mullens W, Linde C, Huizar JF. Electrical management of heart failure: from pathophysiology to treatment. Eur Heart J 2022;43:1917-27.
98. Williams Jr JF, Bristow MR, Fowler MB, et al. Guidelines for the evaluation and management of heart failure: report of the American College of Cardiology/American Heart Association Task Force on Practice guidelines (Committee on Evaluation and Management of Heart Failure). Circulation 1995;92:2764-84.
99. Meyer M, Rambod M, LeWinter M. Pharmacological heart rate lowering in patients with a preserved ejection fraction-review of a failing concept. Heart Fail Rev 2018;23:499-506.
100. Wilcox JE, Rosenberg J, Vallakati A, Gheorghiade M, Shah SJ. Usefulness of electrocardiographic QT interval to predict left ventricular diastolic dysfunction. Am J Cardiol 2011;108:1760-6.
101. Santos AB, Kraigher-Krainer E, Bello N, et al. Left ventricular dyssynchrony in patients with heart failure and preserved ejection fraction. Eur Heart J 2014;35:42-7.
102. Backhaus SJ, Lange T, Schulz A, et al. Cardiovascular magnetic resonance rest and exercise-stress left atrioventricular coupling index to detect diastolic dysfunction. Am J Physiol Heart Circ Physiol 2023;324:H686-95.
103. Infeld M, Wahlberg K, Cicero J, et al. Personalized pacing for diastolic dysfunction and heart failure with preserved ejection fraction: design and rationale for the myPACE randomized controlled trial. Heart Rhythm O2 2022;3:109-16.
104. Wachtell K, Lehto M, Gerdts E, et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan intervention for end point reduction in hypertension (LIFE) study. J Am Coll Cardiol 2005;45:712-9.
105. Fox K, Ford I, Steg PG, Tardif JC, Tendera M, Ferrari R. Ivabradine in stable coronary artery disease without clinical heart failure. N Engl J Med 2014;371:1091-9.
106. Habel N, du Fay de Lavallaz J, Infeld M, et al. Lower heart rates and beta-blockers are associated with new-onset atrial fibrillation. Int J Cardiol Cardiovasc Risk Prev 2023;17:200182.
107. Xiao RP, Tomhave ED, Wang DJ, et al. Age-associated reductions in cardiac beta1- and beta2-adrenergic responses without changes in inhibitory G proteins or receptor kinases. J Clin Invest 1998;101:1273-82.
108. Lorenzo M, Miñana G, Palau P, et al. Lower heart rate in patients with acute heart failure: the role of left ventricular ejection fraction. Scand Cardiovasc J 2024;58:2386977.
109. Anker SD, Butler J, Filippatos G, et al. Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-preserved trial. Eur J Heart Fail 2020;22:2383-92.
110. Infeld M, Avram R, Wahlberg K, et al. An approach towards individualized lower rate settings for pacemakers. Heart Rhythm O2 2020;1:390-3.
111. Meyer M, Infeld M, Habel N, Lustgarten D. Personalized accelerated physiologic pacing. Eur Heart J Suppl 2023;25:G33-43.
112. Meyer M, Lustgarten D. Beta-blockers in atrial fibrillation-trying to make sense of unsettling results. Europace 2023;25:260-2.
113. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. JACC 2022;79:1757-80.
114. Abraham WT, Adamson PB, Bourge RC, et al. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. Lancet 2011;377:658-66.
115. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2002;288:2981-97.
116. Pitt B, Pfeffer MA, Assmann SF, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 2014;370:1383-92.
117. Solomon SD, McMurray JJV, Vaduganathan M, et al. Finerenone in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med 2024;391:1475-85.
118. Kotecha D, Bunting KV, Gill SK, et al. Effect of digoxin vs bisoprolol for heart rate control in atrial fibrillation on patient-reported quality of life: the RATE-AF randomized clinical trial. JAMA 2020;324:2497-508.
119. Al Saikhan L, Chaturvedi N, Ghosh AK, Hardy R, Hughes A. Adulthood adiposity affects cardiac structure and function in later life. Eur Heart J 2024;45:3060-8.
120. Meyer M, LeWinter MM, Zile MR. A targeted treatment opportunity for HFpEF: taking advantage of diastolic tone. Circulation 2021;144:1269-71.
121. Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE study research group. N Engl J Med 1991;325:1468-75.
122. Hiatt WR, Money SR, Brass EP. Long-term safety of cilostazol in patients with peripheral artery disease: the CASTLE study (Cilostazol: a study in long-term effects). J Vasc Surg 2008;47:330-6.
123. McHutchison C, Blair GW, Appleton JP, et al. Cilostazol for secondary prevention of stroke and cognitive decline: systematic review and meta-analysis. Stroke 2020;51:2374-85.
124. Infeld M, Cyr JA, Sánchez-Quintana D, et al. Physiological pacing for the prevention and treatment of heart failure: a state-of-the-art review. J Card Fail 2024;30:1614-28.
125. Infeld M, Wahlberg K, Cicero J, et al. Effect of personalized accelerated pacing on quality of life, physical activity, and atrial fibrillation in patients with preclinical and overt heart failure with preserved ejection fraction: the myPACE randomized clinical trial. JAMA Cardiol 2023;8:213-21.
126. Wahlberg KJ, Infeld M, Plante TB, et al. Effects of continuous accelerated pacing on cardiac structure and function in patients with heart failure with preserved ejection fraction: insights from the myPACE randomized clinical trial. J Am Heart Assoc 2024;13:e032873.
127. Klein FJ, Bell S, Runte KE, et al. Heart rate-induced modifications of concentric left ventricular hypertrophy: exploration of a novel therapeutic concept. Am J Physiol Heart Circ Physiol 2016;311:H1031-9.
128. Riaz S, McMahon SR, Stockey K, Meyer M, Weissler-Snir A. Effect of personalized accelerated pacing in patients with nonobstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 2024;83:1492-3.
129. van Loon T, Rijks J, van Koll J, et al. Accelerated atrial pacing reduces left-heart filling pressure: a combined clinical-computational study. Eur Heart J 2024;45:4953-64.
130. Meyer M. Accelerated pacing as a treatment for heart failure with preserved ejection fraction and atrial fibrillation? Eur Heart J 2024;45:4965-7.
131. Shah SJ, Borlaug BA, Chung ES, et al. Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction (REDUCE LAP-HF II): a randomised, multicentre, blinded, sham-controlled trial. Lancet 2022;399:1130-40.
132. Stone GW, Lindenfeld J, Rodés-Cabau J, et al. Interatrial shunt treatment for heart failure: the randomized RELIEVE-HF trial. Circulation 2024;150:1931-43.
133. Fudim M, Litwin SE, Borlaug BA, et al. Endovascular ablation of the right greater splanchnic nerve in heart failure with preserved ejection fraction: rationale, design and lead-in phase results of the REBALANCE-HF trial. J Card Fail 2024;30:877-89.
134. Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 2017;377:1119-31.
135. Vila Petroff MG, Egan JM, Wang X, Sollott SJ. Glucagon-like peptide-1 increases cAMP but fails to augment contraction in adult rat cardiac myocytes. Circ Res 2001;89:445-52.
